



**Fig. S2. Percentage change in the clinical characteristics of the patients from the time of first dupilumab (DUP) administration in the exacerbation group and remission group.** The x-axis represents: (A) first administration of DUP, (B) 16 weeks after first administration, (C) DUP dosing discontinuation, (D) 4 weeks after DUP dosing discontinuation, (E) 8 weeks after DUP dosing discontinuation, (F) initiation of DUP re-treatment, (G) 16 weeks after DUP re-initiation, and (H) 16 weeks after DUP dosing discontinuation. Error bar is standard error of the mean. IGA: Investigator's Global Assessment; EASI: Eczema Area and Severity Index; DLQI: Dermatology Life Quality Index; POEM: Patient Oriented Eczema Measure; TARC: thymus and activation-regulated chemokine.